Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

2(66.7%)

Phase 3

1(33.3%)

3Total

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials

NCT07709715Phase 3Not Yet Recruiting

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis

Role: lead

NCT06097832Phase 1Active Not Recruiting

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

Role: lead

NCT04720313Phase 1Active Not Recruiting

NXC-201 (formerly HBI0101) Multiple Myeloma

Role: collaborator

All 3 trials loaded